Shidong Jia, MD, PhD, is the Founder and CEO of Predicine. Prior to founding Predicine, Shidong spearheaded the oncology biomarker strategies and drug & diagnostics co-development at Genentech. His previous work identified p110beta as novel drug target for PTEN-deficient tumors, a finding that laid the foundation for clinical development and testing of p110beta inhibitors in cancers. He previously held various senior research positions focusing on translational and clinical cancer research at Novartis Institutes for BioMedical Research and Harvard University. Shidong was awarded the P.A.R.T. Investigatorship Award from the Dana-Farber Cancer Institute. Shidong holds a MD and PhD from Harbin Medical University and Peking Union Medical College, and completed postdoctoral training at the Dana Farber Cancer Institute - Harvard University.